KALV
Kalvista Pharmaceuticals Inc
NASDAQ: KALV · HEALTHCARE · BIOTECHNOLOGY
$26.66
+0.04% today
Updated 2026-05-04
Market cap
$1.42B
P/E ratio
—
P/S ratio
19.29x
EPS (TTM)
$-3.94
Dividend yield
—
52W range
$10 – $27
Volume
2.9M
Kalvista Pharmaceuticals Inc (KALV) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2013 | 2014 | 2014 | 2015 | 2015 | 2016 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-1.83M | $-4.86M | $-11.25M | $-6.37M | $-20.86M | $-5.08M | $-13.16M | $-23.72M | $10.56M | $-36.37M | $-44.82M | $-30.17M | $-78.13M | $-75.26M | $-89.23M | $-152.91M | $-81.62M |
| Capital expenditures | $91000.00 | $18000.00 | $159000.00 | $125000.00 | $659000.00 | $184000.00 | $11000.00 | $74000.00 | $1.43M | $1.08M | $220000.00 | $82000.00 | $931000.00 | $1.20M | $443000.00 | $434000.00 | $1.71M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $47000.00 | $238000.00 | — | $36000.00 | — | — | $118000.00 | $394000.00 | $1.06M | $2.97M | $4.45M | $7.12M | $11.09M | $9.92M | $21.91M | $12.29M | — |
| Free cash flow | $-1.93M | $-4.88M | $-11.41M | $-6.49M | $-21.52M | $-5.27M | $-13.17M | $-23.80M | $9.13M | $-37.45M | $-45.04M | $-30.25M | $-79.06M | $-76.46M | $-89.67M | $-153.34M | $-83.33M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | $0.00 | — | — | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | $49.83M | — | — | $9.19M | $20.11M | $-19.05M | $-16.48M | $34.29M | $-18.69M | $24.27M | — | — | — |